182
Participants
Start Date
July 31, 2013
Primary Completion Date
August 31, 2014
Study Completion Date
August 31, 2014
Hydrocodone ER
Participants were instructed to take hydrocodone ER tablets orally with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
Placebo
During the double-blind titration period used in the original protocol, placebo tablets matching each dose of hydrocodone bitartrate ER tablets (active drug) were used to maintain the blind but not for purposes of comparison.
Teva Investigational Site 10412, Birmingham
Teva Investigational Site 10426, Mobile
Teva Investigational Site 10436, Montgomery
Teva Investigational Site 10363, Phoenix
Teva Investigational Site 10366, Phoenix
Teva Investigational Site 10437, Tucson
Teva Investigational Site 10358, Anaheim
Teva Investigational Site 10408, Bell Gardens
Teva Investigational Site 10425, Carmichael
Teva Investigational Site 10390, Cerritos
Teva Investigational Site 10429, El Cajon
Teva Investigational Site 10423, Escondido
Teva Investigational Site 10391, Huntington Park
Teva Investigational Site 10370, Los Angeles
Teva Investigational Site 10392, Sherman Oaks
Teva Investigational Site 10398, Thousand Oaks
Teva Investigational Site 10428, Torrance
Teva Investigational Site 10361, Walnut Creek
Teva Investigational Site 10369, DeLand
Teva Investigational Site 10379, Fort Lauderdale
Teva Investigational Site 10365, Jacksonville
Teva Investigational Site 10445, Leesburg
Teva Investigational Site 10362, Orlando
Teva Investigational Site 10381, Ormond Beach
Teva Investigational Site 10357, Plantation
Teva Investigational Site 10435, Royal Palm Beach
Teva Investigational Site 10432, Columbus
Teva Investigational Site 10383, Marietta
Teva Investigational Site 10385, Marietta
Teva Investigational Site 10444, Newnan
Teva Investigational Site 10431, Meridian
Teva Investigational Site 10743, Meridian
Teva Investigational Site 10411, Chicago
Teva Investigational Site 10440, Newburgh
Teva Investigational Site 10419, New Orleans
Teva Investigational Site 10359, Shreveport
Teva Investigational Site 10389, Fall River
Teva Investigational Site 10388, Bay City
Teva Investigational Site 10397, Biloxi
Teva Investigational Site 10406, Hazelwood
Teva Investigational Site 10401, St Louis
Teva Investigational Site 10376, Omaha
Teva Investigational Site 10399, Las Vegas
Teva Investigational Site 10409, Berlin
Teva Investigational Site 10439, Buffalo
Teva Investigational Site 10410, New York
Teva Investigational Site 10414, Winston-Salem
Teva Investigational Site 10446, Oklahoma City
Teva Investigational Site 10430, Duncansville
Teva Investigational Site 10386, Mechanicsburg
Teva Investigational Site 10373, Tipton
Teva Investigational Site 10405, Austin
Teva Investigational Site 10364, Dallas
Teva Investigational Site 10372, Dallas
Teva Investigational Site 10371, Houston
Teva Investigational Site 10377, Lake Jackson
Teva Investigational Site 10374, Plano
Teva Investigational Site 10378, San Antonio
Teva Investigational Site 10402, Salt Lake City
Teva Investigational Site 10420, Bellevue
Teva Investigational Site 10433, Everett
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY